II. Indications
- See Glycopeptide Antibiotic
- Refractory Skin and Soft Tissue Infections with failure to respond to maximal oral Antibiotic coverage
III. Mechanism
- See Glycopeptide Antibiotic
- Decreases Bacterial cell wall synthesis
- Similar coverage and mechanism to Vancomycin
- Long-acting agents, with a single Parenteral dose covering entire Antibiotic course
IV. Dosing: Adult Standard
- Adults - Single Dose Regimen
- Give 1500 mg IV once over 30 minutes
- Adults - Two Dose Regimen (one week apart)
- Dose One: 1000 mg IV over 30 minutes
- Dose Two: 500 mg IV over 30 minutes given at one week after first dose
V. Dosing: Adult Renal (eGFR <30 ml/min)
-
General
- Hemodialysis does not remove Dalbavancin (may be given regardless of Hemodialysis timing)
- Adults - Single Dose Regimen
- Give 1125 mg IV once over 30 minutes
- Adults - Two Dose Regimen (one week apart)
- Dose One: 750 mg IV over 30 minutes
- Dose Two: 375 mg IV over 30 minutes given at one week after first dose (if not on Hemodialysis)
VI. Disadvantages
- Expensive ($2500 to $9500 per single dose)
VII. Safety
- Unknown Safety in Pregnancy
- Unknown Safety in Lactation
VIII. Resources
IX. References
- (2014) Presc Lett 21(8): 43
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Antibiotic (T195) , Amino Acid, Peptide, or Protein (T116) |
MSH | C469289 |
LNC | LP35848-8, MTHU018746 |
English | dalbavancin [Chemical/Ingredient], Dalbavancin, DALBAVANCIN, dalbavancin |